Compare LAES & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LAES | TECX |
|---|---|---|
| Founded | 2022 | 2019 |
| Country | Switzerland | United States |
| Employees | N/A | 60 |
| Industry | Semiconductors | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 675.0M | 549.5M |
| IPO Year | 2022 | N/A |
| Metric | LAES | TECX |
|---|---|---|
| Price | $2.83 | $34.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $4.00 | ★ $75.20 |
| AVG Volume (30 Days) | ★ 18.2M | 182.5K |
| Earning Date | 03-31-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $93.36 | N/A |
| Revenue Next Year | $43.06 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.99 | $14.39 |
| 52 Week High | $8.71 | $39.53 |
| Indicator | LAES | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 40.14 | 57.62 |
| Support Level | $2.59 | $27.31 |
| Resistance Level | $3.40 | $35.99 |
| Average True Range (ATR) | 0.23 | 2.47 |
| MACD | -0.04 | 0.25 |
| Stochastic Oscillator | 11.81 | 50.14 |
SEALSQ Corp develops certified secure microcontrollers and implements post-quantum cryptography. The company develops solutions including post-quantum microchips and devices that can be used in a variety of applications, from multi-factor authentication, home automation, and IT network infrastructure to automotive, industrial automation, and control systems. The company's vaultIC range offers a set of ready-to-use secure elements designed to implement embedded security for any kind of device with fast time-to-market and high flexibility. The company's products include VaultIC155, VaultIV18x, VaultIC292, and VaultIC40x. The company generates a majority of its revenue from North America, while it also has its presence in Europe, Middle East & Africa, Asia Pacific, and Latin America.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.